Literature DB >> 31188958

Evidence based decision making between PCI and CABG.

Carlos Collet1.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31188958      PMCID: PMC6555572          DOI: 10.5935/abc.20190076

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


× No keyword cloud information.
For the last five decades, coronary artery bypass grafting (CABG) surgery has been recommended for patients with unprotected left main (ULM) and multivessel coronary artery disease (MVD).[1] In these populations, CABG reduces mortality compared to medical management.[2] In patients with MVD, several randomized clinical trials established the superiority of CABG over percutaneous coronary interventions (PCI) in terms of hard clinical endpoints.[3,4] In the ULM subgroup of the SYNTAX I trial, comparable outcomes between PCI and CABG were observed at five years.[5] This finding triggered the design and execution of the EXCEL and NOBLE trials that confirmed equipoise in major adverse cardiovascular and cerebral events between PCI and CABG in patients with ULM coronary artery disease (CAD).[6,7] The accumulation of evidence has allowed to better understand which patients may benefit from a determined revascularization strategy.[8] In the current issue of the Journal, Negreiros de Andrade et al.[9] present a study-level meta-analysis comparing clinical outcomes after PCI and CABG in patients with ULMCAD and MVD. The authors should be commended for the stratified analysis aiming at providing practical information for the cardiovascular community. Based on the current state of evidence we can state that 1) in patients with ULMCAD, PCI can be considered an alternative to CABG in patients with low anatomical complexity, and 2) patients with MVD have better clinical outcomes when treated with CABG. When these two populations were combined, the present meta-analysis showed an early (<30 days) benefit of PCI in terms of mortality and stroke, and long-term advantage of CABG in death and myocardial infarction. Heart team's interaction is the mainstay of the clinical decision-making process. Key clinical factors such as age, sex, the presence of diabetes mellitus, chronic obstructive pulmonary disease (COPD) and left ventricular ejection fraction should be accounted for in the selection between PCI and CABG. In addition, anatomical consideration based on the presence of isolated ULMCAD and/or MVD must also influence the treatment decision.[8] The SYNTAX score II was developed to aid the heart team in the decision-making process considering the interaction of between clinical variables and anatomical complexity. The score incorporates the clinical variables with the anatomical SYNTAX score providing a treatment recommendation (i.e. PCI or CABG) based on predicted 4-year mortality.[10] Mortality estimation based on individual patient profiles enhances heart team discussion, patient's information and shared decision making. Furthermore, the SYNTAX II score has been validated in contemporary clinical trials; in the EXCEL trial patients randomized to PCI in whom the SYNTAX score II recommended CABG had higher all-cause mortality at 3-year follow-up.[11] Moreover, in the SYNTAX II study, patients with MVD selected based on a mortality risk equipoise between PCI and CABG had similar outcomes compared to a matched population undergoing CABG.[12,13] A practical recommendation, supported by the findings of this meta-analysis are that: females, young patients, diabetics, low-ejection fraction and MVD with high anatomical complexity (e.g. high anatomical SYNTAX score) have better prognosis when treated with CABG, whereas in old patients, with COPD or ULMCAD with low anatomical complexity PCI is an acceptable alternative. Long term data (i.e. 10 years) from the original SYNTAX and FREEDOM have become available and showed a persistent advantage of CABG over PCI in patients with MVD.[3] Long term clinical follow-up of patients with ULMCAD included in EXCEL and NOBLE are awaited to further define the best treatment strategy. Further refinement in the evaluation of patients with ULM and MVD can be achieved using coronary physiology indexes. Systematic use of fractional flow reserve has been shown to reduce the number of lesions that appear to be angiographically significant, reclassify a significant proportion of patients to lower SYNTAX score tertiles and improve clinical outcomes compared to angiographic-guided PCI and optimal medical therapy.[14-16] A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease (FAME 3) will further provide answers on the best revascularization strategy tailoring treatment decision based on coronary physiology. In the near future, virtual tool predicting functional improvement after PCI or CABG will further refine patients' selection potentially improving clinical outcomes in stable CAD.
  14 in total

1.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.

Authors:  Friedrich W Mohr; Marie-Claude Morice; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; Marie-angèle Morel; Nic Van Dyck; Vicki M Houle; Keith D Dawkins; Patrick W Serruys
Journal:  Lancet       Date:  2013-02-23       Impact factor: 79.321

2.  Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.

Authors:  Timo Mäkikallio; Niels R Holm; Mitchell Lindsay; Mark S Spence; Andrejs Erglis; Ian B A Menown; Thor Trovik; Markku Eskola; Hannu Romppanen; Thomas Kellerth; Jan Ravkilde; Lisette O Jensen; Gintaras Kalinauskas; Rikard B A Linder; Markku Pentikainen; Anders Hervold; Adrian Banning; Azfar Zaman; Jamen Cotton; Erlend Eriksen; Sulev Margus; Henrik T Sørensen; Per H Nielsen; Matti Niemelä; Kari Kervinen; Jens F Lassen; Michael Maeng; Keith Oldroyd; Geoff Berg; Simon J Walsh; Colm G Hanratty; Indulis Kumsars; Peteris Stradins; Terje K Steigen; Ole Fröbert; Alastair N J Graham; Petter C Endresen; Matthias Corbascio; Olli Kajander; Uday Trivedi; Juha Hartikainen; Vesa Anttila; David Hildick-Smith; Leif Thuesen; Evald H Christiansen
Journal:  Lancet       Date:  2016-10-31       Impact factor: 79.321

Review 3.  Left main coronary artery disease: pathophysiology, diagnosis, and treatment.

Authors:  Carlos Collet; Davide Capodanno; Yoshinobu Onuma; Adrian Banning; Gregg W Stone; David P Taggart; Joseph Sabik; Patrick W Serruys
Journal:  Nat Rev Cardiol       Date:  2018-06       Impact factor: 32.419

4.  Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study.

Authors:  Michael E Farkouh; Michael Domanski; George D Dangas; Lucas C Godoy; Michael J Mack; Flora S Siami; Taye H Hamza; Binita Shah; Giulio G Stefanini; Mandeep S Sidhu; Jean-François Tanguay; Krishnan Ramanathan; Samin K Sharma; John French; Whady Hueb; David J Cohen; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2018-11-11       Impact factor: 24.094

5.  Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD.

Authors:  Carlos Collet; Yosuke Miyazaki; Nicola Ryan; Taku Asano; Erhan Tenekecioglu; Jeroen Sonck; Daniele Andreini; Manel Sabate; Salvatore Brugaletta; Rodney H Stables; Antonio Bartorelli; Robbert J de Winter; Yuki Katagiri; Ply Chichareon; Giovanni Luigi De Maria; Pannipa Suwannasom; Rafael Cavalcante; Hans Jonker; Marie-Angèle Morel; Bernard Cosyns; Arie P Kappetein; David T Taggart; Vasim Farooq; Javier Escaned; Adrian Banning; Yoshinobu Onuma; Patrick W Serruys
Journal:  J Am Coll Cardiol       Date:  2018-05-22       Impact factor: 24.094

6.  Five-Year Outcomes with PCI Guided by Fractional Flow Reserve.

Authors:  Panagiotis Xaplanteris; Stephane Fournier; Nico H J Pijls; William F Fearon; Emanuele Barbato; Pim A L Tonino; Thomas Engstrøm; Stefan Kääb; Jan-Henk Dambrink; Gilles Rioufol; Gabor G Toth; Zsolt Piroth; Nils Witt; Ole Fröbert; Petr Kala; Axel Linke; Nicola Jagic; Martin Mates; Kreton Mavromatis; Habib Samady; Anand Irimpen; Keith Oldroyd; Gianluca Campo; Martina Rothenbühler; Peter Jüni; Bernard De Bruyne
Journal:  N Engl J Med       Date:  2018-05-22       Impact factor: 91.245

7.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.

Authors:  Pim A L Tonino; Bernard De Bruyne; Nico H J Pijls; Uwe Siebert; Fumiaki Ikeno; Marcel van' t Veer; Volker Klauss; Ganesh Manoharan; Thomas Engstrøm; Keith G Oldroyd; Peter N Ver Lee; Philip A MacCarthy; William F Fearon
Journal:  N Engl J Med       Date:  2009-01-15       Impact factor: 91.245

8.  Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.

Authors:  Marie-Claude Morice; Patrick W Serruys; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; James W Choi; Witold Ruzyllo; Grzegorz Religa; Jian Huang; Kristine Roy; Keith D Dawkins; Friedrich Mohr
Journal:  Circulation       Date:  2014-04-03       Impact factor: 29.690

Review 9.  Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.

Authors:  Stuart J Head; Milan Milojevic; Joost Daemen; Jung-Min Ahn; Eric Boersma; Evald H Christiansen; Michael J Domanski; Michael E Farkouh; Marcus Flather; Valentin Fuster; Mark A Hlatky; Niels R Holm; Whady A Hueb; Masoor Kamalesh; Young-Hak Kim; Timo Mäkikallio; Friedrich W Mohr; Grigorios Papageorgiou; Seung-Jung Park; Alfredo E Rodriguez; Joseph F Sabik; Rodney H Stables; Gregg W Stone; Patrick W Serruys; Arie Pieter Kappetein
Journal:  Lancet       Date:  2018-02-23       Impact factor: 79.321

10.  Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.

Authors:  Javier Escaned; Carlos Collet; Nicola Ryan; Giovanni Luigi De Maria; Simon Walsh; Manel Sabate; Justin Davies; Maciej Lesiak; Raul Moreno; Ignacio Cruz-Gonzalez; Stephan P Hoole; Nick Ej West; J J Piek; Azfar Zaman; Farzin Fath-Ordoubadi; Rodney H Stables; Clare Appleby; Nicolas van Mieghem; Robert Jm van Geuns; Neal Uren; Javier Zueco; Pawel Buszman; Andres Iñiguez; Javier Goicolea; David Hildick-Smith; Andrzej Ochala; Dariusz Dudek; Colm Hanratty; Rafael Cavalcante; Arie Pieter Kappetein; David P Taggart; Gerrit-Anne van Es; Marie-Angèle Morel; Ton de Vries; Yoshinobu Onuma; Vasim Farooq; Patrick W Serruys; Adrian P Banning
Journal:  Eur Heart J       Date:  2017-11-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.